/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Maia Biotechnology Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.12 -0.0508(-5.08%) MAIA at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 1.08
Highest Today 1.195
Today’s Open 1.14
Prev. Close 1.18
52 Week High 2.74
52 Week Low 0.87
Day’s Range: Low 1.08 High 1.195
52-Week Range: Low 0.87 High 2.74
1 day return -
1 Week return -3.44
1 month return +2.28
3 month return -24.83
6 month return -35.63
1 year return -43.71
3 year return -67.34
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 43.70 M

PB Ratio 1066.4451

PE Ratio 0.0

Enterprise Value 33.55 M

Total Assets 10.16 M

Volume 430603

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-17661981 -17.7M, FY22:-15805968 -15.8M, FY21:-13285741 -13.3M, FY20:-6668207 -6.7M, FY19:null 0.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-8903189 -8.9M, Q2/2025:-5346963 -5.3M, Q1/2025:-4517259 -4.5M, Q3/2024:-2735987 -2.7M, Q2/2024:-8879276 -8.9M

Fund house & investment objective

Company Information MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Dr. Vlad Vitoc M.B.A., M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow